{"id":605172,"date":"2026-05-26T17:47:10","date_gmt":"2026-05-26T17:47:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/605172\/"},"modified":"2026-05-26T17:47:10","modified_gmt":"2026-05-26T17:47:10","slug":"brazil-approves-first-generic-semaglutide-pen-after-ozempic-patent-expiry","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/605172\/","title":{"rendered":"Brazil approves first generic semaglutide pen after Ozempic patent expiry"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">SAO PAULO, May 26 (Reuters) &#8211; Brazil&#8217;s health regulator Anvisa said on Tuesday it \u200chad approved EMS&#8217;s Ozivy, the country&#8217;s first \u200csemaglutide-based injector pen, as the drugmaker looks to expand \u200binto a higher-end segment of the global pharmaceutical industry.<\/p>\n<p class=\"yf-1fy9kyt\">The drug uses the same active ingredient as Novo Nordisk&#8217;s diabetes and weight-loss drug \u200cOzempic, whose patent \u2060expired in Brazil in March.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 Drug to be produced at EMS plant \u2060in Sao Paulo state with capacity for up to 40 million pens per year.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 CEO \u200bof Grupo \u200bNC, which controls \u200bEMS, told Reuters \u200cin March the firm expected to launch semaglutide pens this year.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 Following the registration, the drug will be marketed once Brazil&#8217;s medicine pricing chamber approves a price cap.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 For inclusion \u200cin Brazil&#8217;s public healthcare \u200bsystem SUS, Ozivy must be \u200bapproved by \u200bthe Health Ministry.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 Five other synthetic \u200csemaglutide applications and one \u200bbiological version \u200bare under review by Anvisa.<\/p>\n<p class=\"yf-1fy9kyt\">\u2022 EMS rival Hypera had previously said it also planned \u200bto launch \u200cits generic version of semaglutide this year.<\/p>\n<p class=\"yf-1fy9kyt\">(Reporting \u200bby Isabel Teles and Gabriel Araujo; \u200bEditing by Paul Simao)<\/p>\n","protected":false},"excerpt":{"rendered":"SAO PAULO, May 26 (Reuters) &#8211; Brazil&#8217;s health regulator Anvisa said on Tuesday it \u200chad approved EMS&#8217;s Ozivy,&hellip;\n","protected":false},"author":2,"featured_media":605173,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[206348,9548,206349,102,6591,4634,578,56,54,55],"class_list":["post-605172","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-anvisa","tag-brazil","tag-global-pharmaceutical-industry","tag-health","tag-medication","tag-novo-nordisk","tag-ozempic","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/605172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=605172"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/605172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/605173"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=605172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=605172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=605172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}